See AbbVie Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. Other products such as Mavyret and Creon appear to have many more years of blockbuster sales ahead of them, although it is interesting to note that AbbVie no longer reports revenues from its Women's Health division, and scarcely mentions it. AbbVie does not have the funds to pursue any large M&A deals, but it does not need to either, given the strength of its pipeline and products. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. The analysts 12-month consensus ABBV stock price target was $159.75. You should never invest money you cannot afford to lose. AbbVie Oncology Division Forward Revenue Projections (my table and assumtpions). Receive regular, detailed analysis focused on biotech and healthcare stocks. I will conclude this analysis by stating that, based on all available information, market headwinds and tailwinds, competitors, and opportunities via its products and pipeline, I still consider AbbVie to be a strong investment opportunity. Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. AbbVie has 5 focus areas for its research and products. Read our dividend analysis for ABBV. With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. contact@marketbeat.com AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.83%. Trial results demonstrated an overall response rate of 63% and a median duration of response of 12 months, where 39% of patients had already tried a CAR-T cell therapy. Abbvies haematologic oncology portfolio, neuroscience portfolio and aesthetics portfolio reported net revenues of $1.65bn, $1.49bn and $1.37bn, respectively. I hope to see you there. The official website for the company is www.abbvie.com. Only you can design whether Abbvie stock is the right investment for you. AbbVie Stock Forecast 2023 $165.00 In the last five quarters, AbbVie's Price Target has risen from $122.84 to $162.12 - a 31.98% increase. That makes companies like AbbVie generally very attractive to investors although it should be noted that AbbVie carries a very high level of debt which stood at >$60bn as of Q322 - more or less the amount the company paid to acquire Allergan. Aurora Cannabis Revenue Forecast for 2023 - 2025 - 2030. AbbVie's Dividend and Valuation. There are still very few approved therapies, although that could change with Crispr Therapeutics (CRSP) / Vertex (VRTX) Sickle Cell Disease therapy leading the charge in 2023. Price target. See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. What guidance has AbbVie issued on next quarter's earnings? The company reported $3.60 EPS for the quarter, topping the consensus estimate of $3.54 by $0.06. Management are very optimistic on Vraylar, with Gonzalez describing it as "now the only antipsychotic that is a dopamine and serotonin partial agonist approved for the treatment of the most common forms of depression, Bipolar 1 and MDD" and targeting >$5bn peak sales. Pessimistic target level: 151.42 Optimistic target level: 154.48 ABBV (ABBV) Monthly Stock Prediction for 2023 Full forecast for 2023 AbbVie forecast for this year The current consensus among 24 polled investment analysts is to Buy stock in Abbvie Inc. Below, I will outline how I see AbbVie putting the Humira LOE firmly behind it, and driving the high single digit percentage annual growth management has promised. I have no business relationship with any company whose stock is mentioned in this article. Identify stocks that meet your criteria using seven unique stock screeners. AbbVie's free cash flow yield is 10.5% compared to 4.3% for Johnson & Johnson . For ABBVIE INC stock forecast for 2023, 10 predictions are offered for each month of 2023 with average ABBVIE INC stock forecast of $156.58, a high forecast of $160.07, and a low forecast of $152.24. Bhd., AbbVie Sp. I haven't included Epcoritamab sales in my forecasts this time, but I hope to adjust the table before Q3'22 results are announced. Based on earnings estimates, ABBV will have a dividend payout ratio of 54.11% next year. 16 analysts have issued 12-month price targets for AbbVie's shares. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! Year-to-date, the stock was up slightly more than 12% while benchmark global indices have all fallen sharply amid surging inflation, interest rate hikes and slowdown worries. View institutional ownership trends. As we can see, sales of Humira are still climbing, with losses in Europe - where revenues fell by 14% to $699m - offset by growth in the US, to $4.7bn, up 10% year-on-year. . I have been maintaining a revenue forecasting table for AbbVie's products which I have amended based on Q2'22 and H1'22 results, and the slightly downgraded guidance issued for 2022 - management now expects adjusted earnings per share ("EPS") of $13.78 - $13.98, representing growth of 17% at the midpoint. I'm on twitter @edmundingham. The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. Gonzalez has vigorously defended AbbVie against accusations of price manipulation, but the company is renowned for pushing drug prices up annually and should its powerful lobbies become less powerful in the face of external pressure, once again, the sector will start to look unattractive for investors. AbbVie has been increasing its dividend for 51 years. I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. The Abbvie stock forecast for 2025 had the price at $259.018. Sales are expected to recover in H2'22, however, and forecast year-on-year growth. We continue to anticipate a clearer path to strong sales growth in 2025 with high-single-digit compounded annual growth rate to the end of this decade. The important point here is that physicians will not necessarily be under any pressure to switch patients from Humira to a biosimilar, given, as Gonzalez puts it: there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. While some of the gains are due to investor perception that it is a strong company, some view ABBV as a defensive stock, with most of the other stocks in the sector also doing well. For full year 2022, Abbvie predicted the adjusted diluted EPS guidance range at $14.00 to $14.20 and $13.92 to $14.12. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. A Warner Bros. Disclosure: I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. My detailed modeling suggests there is 15-20% upside to look forward to in the short term and that ABBV stock remains a solid long-term buy opportunity for investors. What is the dividend yield for AbbVie? In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most. target price for AbbVie stock based on DCF / EBITDA multiple analysis (my table and assumptions). Build a CFD portfolio with your favourite companies. Investors are already flocking there for a chance at 1,000%+ returns. I am not receiving compensation for it (other than from Seeking Alpha). Abbvie Inc quote is equal to 152.710 USD at 2023-02-27. In my modeling table above, I estimate Humira sales will decline by 25% between 2022 and 2023, to ~$16bn, although some of that lost revenue will be gobbled up by Skyrizi/Rinvoq. AbbVie Inc. is a US-based biopharma company with global operations. The company reported its first revenue for Botox competitor Daxxify. According to the algorithm-based forecaster Wallet Investor in its Abbvie stock forecast for 2022, the price could reach $169.852 by the end of December, $199.491 by 2023 and $229.304 by 2024. In my model I have then reduced revenues by 20% between 2024 - 2026, and then by 10% per annum between 2027 - 2030. Kateryna Onyshchuk/iStock via Getty Images. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tbbi lalar Sanayi ve Ticaret Limited irketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundacin AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC. As with debt, if approval and revenue targets aren't met, it can quickly result in a loss of faith in the company. I wrote this article myself, and it expresses my own opinions. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. However, there are some general principles that can be followed in order to improve the accuracy of stock price predictions. After creating the income statement I prepare the discounted cash flow/EBITDA multiple analysis. First of all, as shown in the table above I forecast product sales out to 2030. Richard A. Gonzalez has an approval rating of 88% among the company's employees. Rinvoq's progress has been a little more circumspect, but almost as impressive. According to 34 stock analysts, the average 12-month stock price forecast for AbbVie stock is $166.14, which predicts an increase of 7.62%. AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. The S&P 500 (US500) lost 9.1%, the Dow Jones (US30) slid 9.7%, and the Nasdaq Composite fell 23% during the same period. Although management reminded analysts that "Imbruvica continues to be the total market share leader across all lines of therapy in CLL", the outlook does not look especially promising. If you have an ad-blocker enabled you may be blocked from proceeding. 326 E 8th St #105, Sioux Falls, SD 57103 (my tables and forecasting). Fawad Razaqzada, market analyst for City Index and FOREX.com, commenting to Capital.com, said: As of 30 June, analyst ratings compiled by MarketBeat shared different price targets for Abbvie stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares. Negative dynamics for AbbVie shares will prevail with possible volatility of 1.976%. AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold, February 24, 2023|americanbankingnews.com, February 23, 2023|americanbankingnews.com. Export data to Excel for your own analysis. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. AbbVie declared a quarterly dividend on Thursday, February 16th. This means that . For the next eight years, the forecast is for Free Cash Flow to grow by . All content of the Dow Jones branded indices S&P Dow Jones Indices LLC 2019 and/or its affiliates. It revealed that patients with moderate to severe Crohns disease receiving Abbvies Rinvoq achieved steroid-free clinical remission in significantly higher numbers than patients receiving a placebo. I had felt this could be an issue for Skyrizi and Rinvoq, given it is rare for a drug to be as dominant as Humira was, but although the level of competition is fierce, both drugs are more than meeting expectations, and with the entire auto-immune market worth as much as $45 - $50bn, it does seem possible that Skyrizi and Rinvoq could one day generate >$20bn revenues between them, as management hopes. The company is a member of the Fortune 100 and one of the Fortune 100s Best Companies To Work For. The development of these 2 drugs has been very quick by drug development standards, and to date both have performed exceptionally well. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year. Both of these assets appear to be doing the job they were intended for - protecting AbbVie's dominance in various auto-immune markets - and now represent ~13% of AbbVie's total revenue generation. Neuroscience is one of AbbVie's most intriguing divisions and perhaps the hardest to model. AbbVie passed that onto its 2022 guidance. . The "King Of Quants" sees 10X potential Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. The Large Pharma sector performed remarkably well in 2022, with the "Big 8" delivering an average ~15% gain whilst the S&P 500 index fell in value, and the biotech sector was in turmoil. Abbvie stock price has put up an impressive performance in 2022. And with a dividend yield of 4.9%, AbbVie is quite attractive for investors yearning for . Is this happening to you frequently? It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community. That is substantially higher than the 12% CAGR achieved between 2018 - 2022, although that period includes the additional revenues from Allergan. Morningstar: 2019 Morningstar, Inc. All Rights Reserved. Their combined revenues are expected to reach $7.5bn in 2022, and Gonzalez told the audience at JPM that: Skyrizi and Rinvoq are now on pace to deliver more than $17.5 billion in combined sales, risk adjusted sales in 2025, well above our previous expectations. AbbVie has been working hard to ensure the 2 drugs it has developed to replace Humira - Skyrizi, which inhibits the pro-inflammatory cytokine IL23, and Rinvoq, a Janus Kinase (enzymes involved in immune cell function) inhibitor - are winning approvals and growing sales in Humira's markets. How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, One Way to Earn More From Dividend Stocks, How to Choose a Winning Dividend Investing Strategy, 3 Industries Leading the Stock Market Rebound, Oil Tankers Boost Dividends, See Continued Robust Business In '23. Based on our forecasts, a long-term increase is expected, the "ABBV" stock price prognosis for 2028-02-23 is 287.522 USD. AbbVie stock forecast 2022 - 2025 - 2030 with analysis AbbVie stock stood at $162.110000610352 on 2022-03-31. forecast for 2023 is $159.42, forecast for 2024 is $156.65, forecast for 2025 is $139.68, forecast for 2026 is $124.48, Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. If you have an ad-blocker enabled you may be blocked from proceeding. But AbbVie is also keen to explore solid tumors, and I am therefore adding an additional $1.5bn of revenues from that source by 2030. Management believes these 2 drugs could one day generate $15bn in peak sales, going a long way to solving the Humira loss of exclusivity ("LOE") problem. Both Leqembi and Donanemab are potential $5bn - $10bn selling assets, but both drugs still have safety questions to answer and not certain to be made eligible for reimbursement. All rights reserved. Ever since its split from Abbott Laboratories (ABT) in 2012 AbbVie (NYSE:ABBV) has delivered strong returns for investors - its stock price having risen overall from $30, to $149 per share at the time of writing - trading down slightly from its all-time high of >$160 achieved in early December last year. I'm on twitter @edmundingham. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". In February, a Phase 3 induction study saw positive top-line results. Is this happening to you frequently? (NYSE: ABBV) Abbvie's current Earnings Per Share (EPS) is $6.65. Since its 2013 separation from Abbott Laboratories (ABT 1.78%), AbbVie's stock has grown more than 160%. Discovery Company. It is generally accepted however that 2023 will see the entrants into the US market of several generic versions of Humira - which works by inhibiting Tumor Necrosis Factor ("TNF"), an inflammation causing protein - from the likes of Viatris (VTRS), Organon (OGN), Pfizer (PFE), Amgen (AMGN), and several more companies involved in the development and sale of generic or biosimilar drugs. Compare Top Brokerages Here. First we can take a quick look at what a forward income statement for AbbVie might look like to 2030. AbbVie product revenue forecasts to 2030. The 21 analysts offering 1 year price forecasts for ABBV have a max estimate of and a min estimate of . In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B - a 8.28% decrease. Skyrizi has also been approved to treat Crohn's Disease, an added bonus and another multi-billion dollar market. AbbVie projected sales - immunology (my forecasts and assumptions). The company employs 50,000 workers across the globe. Shares are consolidating with a buy. AbbVie had a net margin of 20.39% and a trailing twelve-month return on equity of 154.52%. With a 5-year investment, the revenue is expected to be around +88.28%. Other approved ADC's targeting the c-Met protein, a validated target in NSCLC, include Novartis Tabrecta, which has been pegged for peak sales of ~$1.5bn, which seems a realistic target for Teliso given how large the lung cancer market is - the largest of all oncology markets. The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. Read our dividend analysis for ABBV. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. This suggests a possible upside of 3.2% from the stock's current price. On average, analysts forecast that ABBV's EPS will be $11.80 for 2023, with the lowest EPS . There has been a raft of price-moving news for Abbvie, which may positively affect the stock price. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Shares of ABBV stock can be purchased through any online brokerage account. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. 1 dividend stock for a LIFETIME of income. 2022 Cable News Network. I write about Biotech, Pharma and Healthcare stocks and share investment tips. If signs point to that happening I will likely be revising my target price upwards again, but I am playing it more conservative as nobody truly knows the scale of losses after the Humira LOE. I have plugged my revenue expectations into this table knowing that they closely match AbbVie management's own expectations based on what they have said in public. AbbVie (NYSE:ABBV) has a market capitalization of $276.13 billion and generates $58.05 billion in revenue each year. The material provided on this website is for information purposes only and should not be understood as an investment advice. ET comments AbbVie's success - as its shareholders will doubtless be aware - stems from the runaway success of its immunology drug Humira, which is indicated for a range of autoimmune conditions, including Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, Hidradenitis Suppurativa and Ankylosing spondylitis. Management has previously stated that it expects total revenues to decline in 2023 following the Humira LOE, followed by a return to growth in 2024, and a "high single digit CAGR" maintained through the remainder of the decade. Your current $100 investment may be up to $188.28 in 2028. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Capital Com Australia Pty Ltd (ABN 47 625 601 489) is a company registered in Australia and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL 513393. What is Richard A. Gonzalez's approval rating as AbbVie's CEO? CFDs are complex leveraged instruments and come with a high risk of losing money. The five-year dividend growth rate is just below 18%. The company may not generate as much excitement as some of the other members of the "Big 8" - most notably Eli Lilly and its weight loss franchise, but the path to revenue growth, expanding margins and a growing share price is clear. AbbVie is a leader in ESG and sustainability. This year is off to a strong start. Over the next nine years, experts believe that GSK's Free Cash Flow will grow at a rate of 1.98%. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Should I buy or sell AbbVie stock right now? Johnson & Johnson Free Cash Flow Forecast for 2023 - 2025 - 2030. Ltd., AbbVie Overseas S. r.l., AbbVie Oy, AbbVie Participaes Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. (844) 978-6257. In other words, no Humira, no problem! In other words, management believes the LOE of Humira - despite it being the world's best-selling drug - will not hinder growth at the company.
How To Induce Hypomania,
Daily Home Pell City Obituaries,
West Virginia Wesleyan College Notable Alumni,
Articles A
